Abstract Recent studies have revealed in normal thyroid tissue the presence of the transcript of several phosphodiesterases (PDEs), enzymes responsible for the hydrolysis of cyclic nucleotides. In this work, we analyzed the expression of PDE5 in a series of human papillary thyroid carcinomas (PTCs) presenting or not BRAF V600E mutation and classified according to ATA risk criteria. Furthermore, we tested the effects of two PDE5 inhibitors (sildenafil, tadalafil) against human thyroid cancer cells. PDE5 gene and protein expression were analyzed in two different cohorts of PTCs by real-time PCR using a TaqMan microfluid card system and Western blot. MTT and migration assay were used to evaluate the effects of PDE5 inhibitors on proliferation and migration of TPC-1, BCPAP, and 8505C cells. In a first series of 36 PTCs, we found higher expression levels of PDE5A in tumors versus non-tumor (normal) tissues. PTCs with BRAF mutation showed higher levels of mRNA compared with those without mutation. No significant differences were detected between subgroups with low and intermediate ATA risk. Upregulation of PDE5 was also detected in tumor tissue proteins. Similar results were obtained analyzing the second cohort of 50 PTCs. Moreover, all tumor tissues with high PDE5 levels showed reduction of Thyroglobulin, TSH receptor, Thyroperoxidase, and NIS transcripts. In thyroid cancer cells in vitro, sildenafil and tadalafil determined a reduction of proliferation and cellular migration. Our findings demonstrate for the first time an overexpression of PDE5 in PTCs, and the ability of PDE5 inhibitors to block the proliferation of thyroid cancer cells in culture, therefore, suggesting that specific inhibition of PDE5 may be proposed for the treatment of these tumors.
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Introduction
An increase of thyroid carcinomas, and in particular the papillary histotype, has been registered in the last decade [1, 2] . Together with the well-differentiated forms, which are efficaciously managed by the treatment with surgery and radioiodine, an increased prevalence was reported also for the less differentiated carcinomas [1, 3] . These tumors are unable to concentrate this radioisotope and do not respond to the standard treatment or develop radio resistance [4, 5] . These unresponsive tumors are characterized by an altered phenotype, often including the reduction/loss of expression of sodium/iodide symporter (NIS) and thyroperoxidase (TPO), owing to the oncogenic activation of intracellular signal transduction pathways which control cell growth and differentiation [6] [7] [8] [9] . Study of the regulation of intracellular messengers, therefore, may help to identify molecular targets for novel therapeutic approaches. Alterations of intracellular cyclic AMP (cAMP) levels deriving by mutations in the TSH receptor (TSH-R) gene have been extensively investigated, and it is well established their pathogenic role in several thyroid diseases, including hyperfuncting adenomas (gain-of-function mutations) as well as forms of hypothyroidism (inactivating TSHR mutations) [10] [11] [12] . Less defined is the role of cGMP in thyroid cells [13, 14] . Intracellular levels of the cyclic nucleotides are modulated by phosphodiesterases (PDEs), enzymes able to hydrolyze both cAMP and cGMP, and therefore acting as physiological regulators of all the processes mediated by such second messengers [15] . Normal thyroid tissues express subtypes PDE4, PDE5, PDE7, and PDE8 [16] . Moreover, expression of PDE4, able to hydrolyze the cAMP, was also reported to play a regulatory role in toxic adenomas carrying mutations in the TSH-R gene [17] . In contrast, there are no data on the expression of PDE5 (responsible for hydrolysis of cGMP) in thyroid cancer cells.
In this study, we have analyzed the expression of PDE5 in surgical specimens of two series of human papillary thyroid tumor tissues (n = 86, in total), measuring both gene and, when available, protein expression levels, and comparing its expression with those of some thyroidspecific genes. The relationship with BRAF mutational status and other biological features determining clinicpathologic features predicting the risk assessment (low or intermediate category) of recurrence was also investigated.
To verify the possibility to target the PDE5 for therapeutic purpose, we also tested the effects of two PDE5 inhibitors on the growth and migration properties of three human thyroid cell lines derived from papillary (TPC-1 and BCPAP cells) and anaplastic thyroid carcinoma (8505C cells).
Materials and methods

Collection of thyroid tissues
Tumor thyroid tissues were collected from patients subjected to thyroidectomy for PTC at the Sapienza's University Hospital of Rome, Policlinico Umberto I. Two independent cohorts were studied. An exploratory cohort (n = 36) was used for generating the hypothesis, a confirmatory cohort (n = 50) to test it. For each patient, a sample of thyroid tumor tissue and, when available, also contralateral normal tissue was collected, snap-frozen, and stored in liquid nitrogen. All 86 cases were risk-stratified (low or intermediate risk category) on the basis of clinical and pathological features in accordance with the 2009 American Thyroid Association (ATA) initial risk stratification system guidelines [18] , and the presence or not of somatic BRAF V600E mutation detected by direct sequencing was performed in cDNA samples of tumor tissues as described previously [19] . All Patients' tumors information (exploratory and confirmatory cohorts combined) are reported in Table 1 . All human tissue samples used in the study were collected with full Patients' informed written consent and approval from the Policlinico Umberto I Ethical Committee of Rome.
Extraction of RNA and gene expression studies
Total RNA was isolated using TRIzol reagent (Life Technologies, Foster City, CA, USA) following the manufacturer's recommended protocol and quantified with a NanoDrop Spectrophotometer (Thermo Fisher Scientific, Inc., Waltham, MA, USA). cDNAs were obtained following the protocol provided with the High Capacity cDNA Reverse Transcription kit (Life Technologies). To evaluate the expression of PDE5A, NIS, TPO, Thyroglobulin (Tg), and TSH-R genes in thyroid normal and tumor tissues, realtime PCR was performed using custom Taqman Low Density Arrays (TLDA, Life Technologies). Specific predesigned assays were performed to configure each TLDA (TaqMan Gene Expression Assays, Life Technologies) through one replicate for biological sample. Four housekeeping genes (Beta-actin, Glyceraldehyde-3-Phosphate Dehydrogenase, Hypoxanthine Phosphoribosyltransferase 1, and Beta-2 microglobulin) were carried out to normalize RNA expression levels [20] . C T values were calculated through the SDS software (version 2.4) and used to calculate relative quantification (RQ) with RQ Manager software (Life Technologies). In detail, beta-actin was chosen as endogenous control due to its lower variation among samples, and final results were expressed as relative expression normalized to a calibrator sample.
Protein extraction and western blot analysis
Extraction of total proteins was performed as previously described [21] . 20 lg of proteins was run on a 9 or 12 % SDS-PAGE gel, transferred to PVDF membrane (2 h at 225 mA) (VWR, Milan, Italy), blocked with TTBS/milk (TBS, 1 % Tween 20 and 5 % non-fat dry milk) and incubated overnight with affinity-purified anti-PDE5 (Santa Cruz, Milan, Italy), diluted 1:500 for tissues and 1:100 for cells and anti-b-actin antibodies (Sigma Aldrich, Segrate, Milan, Italy) (used as internal control) diluted 1:10,000. The membranes were washed in TTBS and incubated with horseradish peroxidase-conjugated anti-rabbit or antimouse antibody (Transduction Laboratories, Lexington, KY, USA) diluted 1:10,000 or 1:20,000 in TTBS/milk. The protein was visualized by chemiluminescence using the Western blot detection system ECL (VWR) and Western lightning Plus-ECL (Perkin Elmer, Milan, Italy). Quantification was achieved by densitometric scanning.
Thyroid cancer cell lines
For in vitro experiment, we used human papillary (BCPAP and TPC-1, provided by Prof. A. Fusco) and anaplastic (8505C provided by Dr. C. Nucera) thyroid carcinoma cell lines, confirmed as of thyroid cancer origin and hosting the RET-PTC (TPC-1) or BRAF (BCPAP and 8505C) genotypic alteration, respectively [22] . The cells were cultured as previously described [23, 24] .
MTT assay
TPC-1, BCPAP, and 8505C cells were seeded in 96-well plates at a density of 3 9 10 3 (TPC-1 and 8505C) or 5 9 10 3 (BCPAP). Proliferation was assessed by MTT [25] . After 24 h, growth medium was replaced by fresh normal medium supplemented with sildenafil and tadalafil (Aurogene, Roma, Italy) (1, 10, 100 lM), and cells were incubated for 24 and 48 h. Then, the solubilized product was quantified with a microplate spectrophotometer (Multiskan MS 6.0, Labsystems) at a wavelength of 540 nm and a reference wavelength of 690 nm. Results are expressed as percentages over untreated cultures (control).
Migration assay
Cell migration assay was performed using Transwell inserts with 8 lm pore (Constar; Euroclone, Milan, Italy), as previously described [26] . Briefly, cells were treated with sildenafil (0.01, 0.1, 1, and 10 lM) and tadalafil (0.01, 0.1, 1, and 10 lM) for 24 h, trypsinized, and centrifuged (1200 rpm for 5 min). After suspension in medium without serum, the pellet was centrifuged (1200 rpm for 5 min) and suspended in medium containing 1 % BSA. Then, the cells were plated in the upper chamber of filters at a density of 50 9 10 3 cells (in 100 lL) while in the inferior chamber were added 600 lL of medium containing 10 % FBS. After 6 h of incubation, cells not migrated were removed from the upper surface of the filters with cotton swabs, while the filters were fixed and stained with Diff-Quick. Migrated cells were counted in five random fields using an eyepiece equipped with a counting grid.
Statistical analysis
The results are expressed as mean ± standard deviation (SD). For cell proliferation and cell migration assay was adopted the one-way ANOVA followed by the TukeyKramer multiple comparisons test using GraphPad Prism version 5.0 statistical software (GraphPad Software Inc., San Diego, CA, USA). Analysis of mRNA levels was performed by Mann-Whitney test. p values lower than 0.05 were considered statistically significant.
Results
Gene and protein expression of PDE5 and clinicalpathological features of PTCs
We first examined by TLDA the expression of PDE5A in a series of 36 tissues from patients with sporadic PTC (exploratory cohort). These tumors, according to ATA risk classification system, included 17 with a low degree of risk and 19 with intermediate risk. Among them, 7 and 14 carry the BRAF V600E mutation, respectively (Table 1) .
Expression levels of PDE5A resulted significantly higher in the tumor tissues compared to a pool of nontumor (normal) tissues and also in BRAF V600E, when compared with BRAF wild-type PTCs (p \ 0.0001 and p \ 0.01, respectively). No differences were observed between low risk and intermediate risk PTCs (Fig. 1a) . This analysis was replicated in a wider and independent cohort of patients with sporadic PTCs (n = 50), and results were confirmed (Fig. 1b) .
Data of PDE5A transcript levels were then compared with those of the thyroid-specific genes NIS, TPO, Tg, and TSH-R. As shown in Fig. 2 , while almost all tumor samples had higher PDE5A expression levels as compared to normal samples, they displayed significantly lower mRNA levels of thyroid-specific genes (Fig. 2) .
Subsequently, Western blot analysis performed in protein extracts of a series of PTCs showed higher level of protein expression in tumor tissues compared to normal counterpart (Fig. 3) , confirming the finding obtained with mRNA analysis.
Effects of sildenafil and tadalafil on proliferation and migration of thyroid cancer cells
To evaluate the effects of PDE5 inhibition on thyroid tumor cells, we examined viability and migration properties of BCPAP, TPC-1 (from PTC), and 8505C (from ATC) cells incubated with sildenafil and tadalafil, two different specific inhibitors of PDE5. All cell lines showed detectable levels of PDE5 (Fig. 4) . As shown in Fig. 5 , treatment with 1, 10, 100 lM of sildenafil or tadalafil for 24 and 48 h reduced the proliferation of all three cell lines with similar trend. In particular, the strongest inhibiting effect (about 50 % vs. control) was observed using the 100 lM concentration of tadalafil in all cell lines (p \ 0.05, p \ 0.01, p \ 0.001 vs. control). At the same concentration, minor but significant effect was exerted by sildenafil on BCPAP and 8505C cells after 48 h (p \ 0.05, p \ 0.01 vs. control).
Next, effects of PDE5 inhibitors on cell migration were evaluated. As shown in Fig. 6 , in BCPAP and 8505C cell lines, a reduction of the migration was observed at 0.1, 1, and 10 lM (8505C and BCPAP cells *50 % vs. untreated cells; p \ 0.001 and 0.05, respectively).
Interestingly and in accordance with our previous in vivo data on BRAF mutated tumors, the cells carrying the BRAF V600E mutation (8505C and BCPAP) showed a better response to PDE5 inhibition in both anti-proliferative and anti-migration action of both inhibitors.
Discussion
Novel approaches are currently under investigation for the management of those differentiated thyroid cancers refractory to radioiodine therapy. A major alteration detected in such thyroid cancer cells regards the machinery responsible for iodide uptake and concentration, primary involving the sodium/iodide symporter, caused by genetic and epigenetic abnormalities especially detected in metastatic lesions [27] [28] [29] [30] [31] . Almost all the known genetic alterations occur in elements of signal transduction pathways controlling both cell growth and differentiation. In PTCs, activating BRAF mutation represents the most frequent genetic alteration and is also considered as a marker of aggressiveness [32] [33] [34] [35] . Fig. 1 mRNA levels 
At variance with cAMP and its pathway, widely investigated as the main mediator of the TSH effects on thyroid cells and involved in several thyroid diseases [10] , the role of the regulation of cGMP, mainly exerted by PDEs, in thyroid cancer has never been investigated. PDEs may be considered a key therapeutic target, and quantitative RT-PCR analysis has revealed the mRNA expression profile of all PDE isoenzymes in human brain and peripheral tissues and in normal thyroid gland, which expressed the transcripts of PDE4, PDE7, PDE8, and PDE5 [16] . The latter enzyme acts specifically hydrolyzing the cGMP and is encoded by one gene, PDE5A, with three variants: PDE5A1 (*100 kDa), PDE5A2 (*95 kDa), and PDE5A3 (*95 kDa) [36] .
Our results show for the first time an increased expression of PDE5, both at mRNA and protein levels, in a total of 86 PTCs belonging to two independent cohorts. Increased transcript of PDE5A was also associated with decrease of the transcript of some differentiation markers as TSH-R, Tg, TPO, and NIS, all implicated in intra-thyroidal iodine metabolism and thyroid hormone synthesis. Moreover, by analyzing the clinicobiological chart of the patients, we noted presence of higher expression levels of PDE in PTCs with BRAF V600E mutation. However, increase of PDE5A mRNA levels cannot be associated with the aggressiveness of the tumors, since no differences were observed comparing the subgroups classified according to the 2009 ATA criteria risk stratification system as low and intermediate risk. Interestingly, in a parallel study focusing on genome abnormality, amplification of PDE5A gene resulted a frequent lesion detected in PTCs, independent from their aggressiveness (unpublished observation).
The present findings prompted us to test the effects of PDE5 inhibition in thyroid cancer cells. We considered as bona fide results those determined in a concordant way by two different PDE5 inhibitors, sildenafil and tadalafil, currently approved for use in male erectile dysfunction and in pulmonary hypertension [37] [38] [39] [40] . Moreover, there is considerable excitement regarding the potential use of PDE5 inhibitors as therapeutics for cardiovascular diseases, including hypertension, ischaemic cardiomyopathy, cardiac failure, stroke, peripheral myopathy, and cardiac dysfunction in Duchenne muscular dystrophy, as well as insulin resistance, type 2 diabetes, and metabolic syndrome, and several clinical trials are in progress [41] . Various PDE1 to PDE5 selective inhibitors have also been reported to inhibit growth and induce apoptosis in many different cancer cell lines, suggesting a potential role for this family of drugs also as antineoplastic agents [41] .
We found a significant inhibitory action of both molecules on the growth of three human cancer cell lines. At lower doses, sildenafil and tadalafil were also able to reduce the capacity of the tumor cells to migrate, a fundamental step for the metastatic spread of the neoplastic disease. Also, the effects of sildenafil and tadalafil were stronger in the cell lines (BCPAP and 8505C) carrying the BRAF mutation. Together with our in vivo results, higher expression of PDE5 in BRAF mutated tumors, this finding would suggest that these PTCs could represent a preferential target for the action of PDE5 inhibitors.
In conclusion, our finding demonstrate for the first time an overexpression of PDE5 in PTCs and the ability of PDE5 inhibitors to block the proliferation of thyroid cancer cells in culture. Further studies in experimental models in vivo will clarify whether specific inhibition of PDE5 may be proposed for the treatment of these tumors.
